The drug, also known as ribociclib ... Additionally, FDA also approved the ribociclib and letrozole co-pack (Kisqali Femara ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

The US Food and Drug Administration (FDA) has approved Kisqali for early stage breast treatment. Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help ...